Rapid Micro Biosystems (NASDAQ:RPID) Releases Quarterly Earnings Results, Meets Estimates

Rapid Micro Biosystems (NASDAQ:RPID) issued its quarterly earnings results on Friday. The company reported ($0.26) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.26), Zacks reports. Rapid Micro Biosystems had a negative net margin of 145.63% and a negative return on equity of 63.07%. The company had revenue of $7.84 million during the quarter, compared to analysts’ expectations of $7.60 million. Rapid Micro Biosystems updated its FY 2025 guidance to EPS.

Rapid Micro Biosystems Stock Performance

Shares of RPID traded up $0.35 on Friday, hitting $3.10. 127,335 shares of the stock traded hands, compared to its average volume of 82,886. Rapid Micro Biosystems has a one year low of $0.87 and a one year high of $4.50. The company has a market capitalization of $137.05 million, a PE ratio of -3.07 and a beta of 1.37. The business has a 50 day simple moving average of $3.06 and a 200 day simple moving average of $3.13.

Institutional Trading of Rapid Micro Biosystems

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Rapid Micro Biosystems by 6.7% in the third quarter. Vanguard Group Inc. now owns 965,018 shares of the company’s stock worth $3,223,000 after purchasing an additional 60,655 shares during the last quarter. XTX Topco Ltd bought a new stake in Rapid Micro Biosystems in the 2nd quarter worth about $144,000. American Century Companies Inc. raised its position in Rapid Micro Biosystems by 46.1% in the 2nd quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock worth $58,000 after buying an additional 5,341 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Rapid Micro Biosystems by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 204,079 shares of the company’s stock valued at $704,000 after acquiring an additional 3,143 shares during the period. Institutional investors own 52.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on RPID. Wall Street Zen raised shares of Rapid Micro Biosystems from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Wednesday, October 8th. Finally, Lake Street Capital began coverage on Rapid Micro Biosystems in a research note on Monday, July 28th. They set a “buy” rating and a $8.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Rapid Micro Biosystems currently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems, Inc, a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.